|
| Product Name: | Vantas | | Synonyms: | Supprelin la;Vantas;Histrelin acetate, >=98%;(Des-Gly10,D-His(Bzl)6,Pro-NHEt 9)-LHRH acetate salt Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt acetate salt;Histrelin?Acetate impurity;Vantas USP/EP/BP;Histrelin Acetate(acetate);(Des-Gly??,D-His(Bzl)?,Pro-NHEt?)-LHRH acetate salt | | CAS: | 220810-26-4 | | MF: | C66H86N18O12 | | MW: | 1323.52 | | EINECS: | | | Product Categories: | | | Mol File: | 220810-26-4.mol |  |
| | Vantas Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 0.25 mg/ml; PBS (pH 7.2): 10 mg/ml | | form | A crystalline solid |
| | Vantas Usage And Synthesis |
| Description | Histrelin is a synthetic gonadotropin-releasing hormone (GNRH) agonist that binds to the GNRH receptor (GNRHR; Ki = 0.2 nM in CHO cells expressing the human receptor). It stimulates release of oxytocin and vasopressin ex vivo from the isolated rat hypothalamo-neurohypophysial system at a concentration of 100 nM. In vivo, the initial dose of histrelin (100 μg) stimulates acute increases in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone serum levels (50-, 2.5-, and 15-fold, respectively), while chronic treatment leads to 95% decreases in LH and FSH responses in rhesus monkeys. Formulations containing histrelin have been used in the treatment of advanced prostate cancer and central precocious puberty. | | Definition | ChEBI: An acetate salt obtained by combining histrelin with acetic acid. The amount of acetic acid present can vary and a variable amount of water may be present. Histrelin acetate is used as a subcutaneous hydrogel implant for the treatment of prostate cancer an
for the suppression of gonadal sex hormone production in children with central precocious puberty. |
| | Vantas Preparation Products And Raw materials |
|
